DexTech Medical files a new patent application with the European Patent Office

Dextech has filed a new patent application regarding GMP production (Good Manufacturing Practice) of the company's lead candidate OsteoDex with the European Patent Office (EPO.Org). The application describes a GMP synthesis method on a larger scale that results in a pharmaceutical-grade product as well as OsteoDex use for the treatment of cancer that develops in the bones.

The application is of great importance for the Company's planned clinical further development of OsteoDex (phase 3, castration-resistant prostate cancer) together with a major partner.

"- A synthesis patent will have a strong positive impact on our ability to secure OsteoDex's resource-intensive continued clinical development. The patent protection will extend until about 2044 and I see the conditions for a granted patent as very good," says CEO Anders R Holmberg.

For more information about DexTech, please contact:

Gösta Lundgren – CFO

DexTech Medical AB

Phone: +46 (0) 707104788

E-mail: [email protected]

This information is information that DexTech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on October 13, 2023.

DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. A successful clinical phase II study has been conducted with OsteoDex where the results show high tolerability with mild side effects and treatment effect on patients who fail on existing drugs. DexTech's goal is to out-license each drug candidate no later than after completion of the phase II study. DexTech Medical AB is listed on Spotlight Stock Market.